Yu-Pei Chen1, Ying Sun1, Lei Chen1, Yan-Ping Mao1, Ling-Long Tang1, Wen-Fei Li1, Xu Liu1, Wen-Na Zhang1, Guan-Qun Zhou1, Rui Guo1, Ai-Hua Lin2, Jun Ma3. 1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. 2. Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China. 3. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. Electronic address: majun2@mail.sysu.edu.cn.
Abstract
BACKGROUND AND PURPOSE: We used a literature-based meta-analysis to assess whether failure-free survival (FFS) or progression-free survival (PFS) could be reliable surrogate endpoints for overall survival (OS) in trials of combined chemotherapy and radiotherapy for nasopharyngeal carcinoma (NPC). METHODS AND MATERIALS: We identified randomised trials that evaluated combined chemoradiotherapy strategies, and reported FFS or PFS and OS in NPC. We analysed the treatment effects on FFS or PFS, and OS. We used the coefficient of determination (R(2)), and the surrogate threshold effect (STE) to assess the trial-level correlation. RESULTS: Twenty-one trials (5212 patients), with sixteen treatment-control comparisons for FFS, and nine for PFS, were analysed. FFS was strongly correlated with OS (R(2)=0.88, STE=0.84), as was PFS (R(2)=0.90, STE=0.88). Moreover, FFS and PFS at 3 years were still strongly correlated with 5-year OS (R(2)=0.80, STE=0.83; R(2)=0.85, STE=0.84). CONCLUSIONS: Both FFS and PFS could be valid surrogate endpoints for OS in trials of combined chemotherapy and radiotherapy for NPC; PFS may be a more acceptable surrogate endpoint compared with FFS.
BACKGROUND AND PURPOSE: We used a literature-based meta-analysis to assess whether failure-free survival (FFS) or progression-free survival (PFS) could be reliable surrogate endpoints for overall survival (OS) in trials of combined chemotherapy and radiotherapy for nasopharyngeal carcinoma (NPC). METHODS AND MATERIALS: We identified randomised trials that evaluated combined chemoradiotherapy strategies, and reported FFS or PFS and OS in NPC. We analysed the treatment effects on FFS or PFS, and OS. We used the coefficient of determination (R(2)), and the surrogate threshold effect (STE) to assess the trial-level correlation. RESULTS: Twenty-one trials (5212 patients), with sixteen treatment-control comparisons for FFS, and nine for PFS, were analysed. FFS was strongly correlated with OS (R(2)=0.88, STE=0.84), as was PFS (R(2)=0.90, STE=0.88). Moreover, FFS and PFS at 3 years were still strongly correlated with 5-year OS (R(2)=0.80, STE=0.83; R(2)=0.85, STE=0.84). CONCLUSIONS: Both FFS and PFS could be valid surrogate endpoints for OS in trials of combined chemotherapy and radiotherapy for NPC; PFS may be a more acceptable surrogate endpoint compared with FFS.
Authors: Federico Rotolo; Jean-Pierre Pignon; Jean Bourhis; Sophie Marguet; Julie Leclercq; Wai Tong Ng; Jun Ma; Anthony T C Chan; Pei-Yu Huang; Guopei Zhu; Daniel T T Chua; Yong Chen; Hai-Qiang Mai; Dora L W Kwong; Yoke Lim Soong; James Moon; Yuk Tung; Kwan-Hwa Chi; George Fountzilas; Li Zhang; Edwin Pun Hui; Anne W M Lee; Pierre Blanchard; Stefan Michiels Journal: J Natl Cancer Inst Date: 2017-04 Impact factor: 13.506
Authors: Ling-Long Tang; Shao-Bo Liang; Cheng-Long Huang; Fan Zhang; Cheng Xu; Yan-Ping Mao; Li Tian; Ai-Hua Lin; Li Li; Ying Sun; Jun Ma Journal: Cancer Med Date: 2019-04-04 Impact factor: 4.452